Share Price and Basic Stock Data
Last Updated: December 5, 2025, 3:31 am
| PEG Ratio | -10.85 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Biocon Ltd, a prominent player in the pharmaceuticals industry, reported a stock price of ₹388 with a market capitalization of ₹51,921 Cr. The company has demonstrated significant revenue growth, with sales rising from ₹8,184 Cr in FY 2022 to ₹11,174 Cr in FY 2023, and further to ₹14,756 Cr in FY 2024. The trailing twelve months (TTM) revenue stood at ₹15,771 Cr, indicating a steady upward trajectory. Quarterly sales figures reveal fluctuations, peaking at ₹3,774 Cr in Mar 2023 before settling at ₹3,462 Cr in Sep 2023. This volatility may reflect market dynamics and competitive pressures. The company’s operational efficiency, measured by an operating profit margin (OPM) of 19%, suggests a solid ability to manage costs relative to sales. Biocon’s focus on expanding its biologics portfolio and biosimilars has positioned it favorably within the sector, emphasizing the need for continuous innovation to maintain growth. Overall, the company’s revenue trajectory highlights its resilience and adaptability in a competitive landscape.
Profitability and Efficiency Metrics
Biocon reported a net profit of ₹657 Cr for the latest fiscal year, with a modest return on equity (ROE) of 4.76% and return on capital employed (ROCE) of 6.25%. These figures indicate that while the company is generating profits, the returns on equity and capital employed are relatively low compared to sector standards. The interest coverage ratio (ICR) stood at 4.87x, showcasing the company’s ability to cover its interest expenses comfortably. However, the profit margins exhibited variability, with operating profit margins fluctuating between 17% and 25% across the past year. This inconsistency in profitability may arise from variations in operational efficiency and cost management strategies. The company also recorded a net profit margin of 9.36% in FY 2025, reflecting challenges in sustaining profitability amidst rising costs. Biocon’s capacity to enhance these profitability metrics will be crucial for its long-term sustainability and investor confidence.
Balance Sheet Strength and Financial Ratios
Biocon’s balance sheet reveals a total debt of ₹16,536 Cr against reserves of ₹26,135 Cr, indicating a relatively healthy capital structure. The company’s current ratio of 1.14x suggests adequate liquidity to meet short-term obligations, while a quick ratio of 0.79x points to potential liquidity challenges in a tighter cash flow environment. The debt-to-equity ratio stands at 0.82x, which is within acceptable limits for the pharmaceuticals sector, although it indicates a reliance on debt financing. The book value per share, recorded at ₹180.27, provides a buffer for investors regarding the company’s underlying asset value. Furthermore, Biocon’s enterprise value (EV) of ₹60,668.27 Cr relative to its net operating revenue highlights a reasonable valuation, although the EV/EBITDA ratio of 13.87x suggests that the stock may not be undervalued. Strengthening its balance sheet further through effective cash flow management and debt reduction strategies will be essential for enhancing financial stability.
Shareholding Pattern and Investor Confidence
Biocon’s shareholding structure is characterized by a strong promoter stake of 54.45%, which reflects substantial management confidence in the company’s future. This is complemented by a growing institutional investor presence, with foreign institutional investors (FIIs) holding 6.61% and domestic institutional investors (DIIs) at 22.06%. The gradual increase in DII ownership from 8.63% in Dec 2022 to 22.83% in Jun 2025 indicates rising institutional confidence in Biocon’s strategic direction and growth potential. The number of shareholders has also increased to 4,13,191, demonstrating broader public interest in the stock. However, the declining promoter share from 60.64% in Mar 2023 to 54.45% in Jun 2025 may warrant scrutiny regarding long-term management commitment. Overall, the shareholding pattern reflects a blend of stability and evolving investor sentiment, which can influence market performance significantly.
Outlook, Risks, and Final Insight
Looking ahead, Biocon faces both opportunities and challenges that will shape its trajectory. The company’s focus on biologics and biosimilars positions it well in a growing market, but it must navigate risks such as regulatory hurdles and intense competition. The variability in profit margins and relatively low ROE highlight the need for operational improvements and cost management initiatives. Additionally, the increasing debt levels could pose risks in a rising interest rate environment, potentially affecting profitability. To mitigate these risks, Biocon should prioritize strategic investments in R&D and operational efficiencies. Enhancing shareholder value through consistent profitability and prudent financial management will be critical for maintaining investor confidence. If Biocon can successfully implement these strategies, it has the potential to strengthen its market position and deliver sustainable growth in the long term.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Biocon Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 148 Cr. | 118 | 247/84.3 | 32.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,222 Cr. | 387 | 479/192 | 87.4 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.4 Cr. | 47.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.1 Cr. | 29.4 | 30.5/17.0 | 103 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,616.17 Cr | 1,175.51 | 52.55 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,140 | 2,320 | 2,941 | 3,774 | 3,423 | 3,462 | 3,954 | 3,917 | 3,433 | 3,590 | 3,821 | 4,417 | 3,942 |
| Expenses | 1,783 | 1,877 | 2,352 | 2,817 | 2,741 | 2,745 | 3,051 | 3,004 | 2,812 | 2,905 | 3,070 | 3,339 | 3,193 |
| Operating Profit | 356 | 442 | 589 | 957 | 681 | 717 | 903 | 913 | 620 | 685 | 752 | 1,078 | 749 |
| OPM % | 17% | 19% | 20% | 25% | 20% | 21% | 23% | 23% | 18% | 19% | 20% | 24% | 19% |
| Other Income | 78 | 48 | -193 | 152 | 94 | 134 | 587 | 40 | 1,166 | 58 | 53 | 57 | 80 |
| Interest | 20 | 30 | 120 | 249 | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 |
| Depreciation | 218 | 231 | 301 | 364 | 358 | 389 | 414 | 407 | 405 | 420 | 425 | 436 | 455 |
| Profit before tax | 197 | 229 | -26 | 497 | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 | 97 |
| Tax % | 15% | 64% | -19% | 17% | 19% | 19% | 7% | 30% | 25% | 72% | 48% | 6% | 8% |
| Net Profit | 167 | 82 | -21 | 414 | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 |
| EPS in Rs | 1.20 | 0.39 | -0.35 | 2.61 | 0.84 | 1.05 | 5.50 | 1.13 | 5.49 | -0.13 | 0.21 | 2.87 | 0.23 |
Last Updated: August 20, 2025, 12:45 pm
Below is a detailed analysis of the quarterly data for Biocon Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 3,942.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4,417.00 Cr. (Mar 2025) to 3,942.00 Cr., marking a decrease of 475.00 Cr..
- For Expenses, as of Jun 2025, the value is 3,193.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3,339.00 Cr. (Mar 2025) to 3,193.00 Cr., marking a decrease of 146.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 749.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,078.00 Cr. (Mar 2025) to 749.00 Cr., marking a decrease of 329.00 Cr..
- For OPM %, as of Jun 2025, the value is 19.00%. The value appears to be declining and may need further review. It has decreased from 24.00% (Mar 2025) to 19.00%, marking a decrease of 5.00%.
- For Other Income, as of Jun 2025, the value is 80.00 Cr.. The value appears strong and on an upward trend. It has increased from 57.00 Cr. (Mar 2025) to 80.00 Cr., marking an increase of 23.00 Cr..
- For Interest, as of Jun 2025, the value is 277.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 212.00 Cr. (Mar 2025) to 277.00 Cr., marking an increase of 65.00 Cr..
- For Depreciation, as of Jun 2025, the value is 455.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 436.00 Cr. (Mar 2025) to 455.00 Cr., marking an increase of 19.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 97.00 Cr.. The value appears to be declining and may need further review. It has decreased from 487.00 Cr. (Mar 2025) to 97.00 Cr., marking a decrease of 390.00 Cr..
- For Tax %, as of Jun 2025, the value is 8.00%. The value appears to be increasing, which may not be favorable. It has increased from 6.00% (Mar 2025) to 8.00%, marking an increase of 2.00%.
- For Net Profit, as of Jun 2025, the value is 89.00 Cr.. The value appears to be declining and may need further review. It has decreased from 459.00 Cr. (Mar 2025) to 89.00 Cr., marking a decrease of 370.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.23. The value appears to be declining and may need further review. It has decreased from 2.87 (Mar 2025) to 0.23, marking a decrease of 2.64.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:35 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,877 | 3,090 | 3,347 | 3,891 | 4,123 | 5,514 | 6,367 | 7,143 | 8,184 | 11,174 | 14,756 | 15,262 | 15,771 |
| Expenses | 2,190 | 2,394 | 2,957 | 2,912 | 3,294 | 4,121 | 4,792 | 5,562 | 6,391 | 8,762 | 11,540 | 12,008 | 12,506 |
| Operating Profit | 687 | 696 | 390 | 980 | 829 | 1,394 | 1,575 | 1,581 | 1,793 | 2,412 | 3,216 | 3,254 | 3,264 |
| OPM % | 24% | 23% | 12% | 25% | 20% | 25% | 25% | 22% | 22% | 22% | 22% | 21% | 21% |
| Other Income | 56 | 158 | 639 | 173 | 228 | 340 | 228 | 260 | 72 | 18 | 853 | 1,217 | 248 |
| Interest | 2 | 9 | 29 | 26 | 62 | 71 | 65 | 58 | 68 | 419 | 974 | 897 | 938 |
| Depreciation | 204 | 221 | 249 | 277 | 385 | 448 | 552 | 715 | 814 | 1,113 | 1,569 | 1,687 | 1,737 |
| Profit before tax | 538 | 624 | 751 | 850 | 610 | 1,215 | 1,186 | 1,068 | 983 | 897 | 1,525 | 1,887 | 838 |
| Tax % | 20% | 15% | 19% | 19% | 26% | 17% | 27% | 21% | 22% | 28% | 15% | 24% | |
| Net Profit | 431 | 528 | 609 | 688 | 453 | 1,003 | 871 | 846 | 772 | 643 | 1,298 | 1,429 | 657 |
| EPS in Rs | 3.45 | 4.14 | 4.59 | 5.10 | 3.10 | 7.54 | 6.24 | 6.17 | 5.40 | 3.85 | 8.52 | 8.44 | 3.18 |
| Dividend Payout % | 24% | 20% | 18% | 10% | 16% | 7% | 0% | 0% | 9% | 39% | 6% | 6% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 22.51% | 15.34% | 12.97% | -34.16% | 121.41% | -13.16% | -2.87% | -8.75% | -16.71% | 101.87% | 10.09% |
| Change in YoY Net Profit Growth (%) | 0.00% | -7.16% | -2.37% | -47.13% | 155.57% | -134.57% | 10.29% | -5.88% | -7.96% | 118.58% | -91.77% |
Biocon Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 19% |
| 3 Years: | 23% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 7% |
| 3 Years: | 10% |
| TTM: | -77% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | -3% |
| 3 Years: | 7% |
| 1 Year: | -6% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 6% |
| 3 Years: | 5% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 1:00 am
Balance Sheet
Last Updated: December 4, 2025, 1:03 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 100 | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 | 600 | 668 |
| Reserves | 2,927 | 3,171 | 3,934 | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 | 19,183 | 21,044 | 26,135 |
| Borrowings | 864 | 1,117 | 2,478 | 2,302 | 2,264 | 2,422 | 2,715 | 4,481 | 5,147 | 18,019 | 16,277 | 18,362 | 16,536 |
| Other Liabilities | 1,860 | 1,988 | 1,947 | 2,254 | 2,545 | 3,672 | 4,993 | 6,382 | 6,763 | 15,856 | 19,693 | 18,534 | 19,421 |
| Total Liabilities | 5,751 | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,414 | 18,490 | 20,342 | 51,742 | 55,753 | 58,540 | 62,760 |
| Fixed Assets | 1,525 | 1,630 | 1,748 | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 29,468 | 30,644 | 31,963 | 37,262 |
| CWIP | 1,206 | 1,677 | 2,240 | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 7,317 | 7,993 | 8,508 | 4,651 |
| Investments | 765 | 230 | 902 | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 | 1,000 | 1,127 | 2,333 |
| Other Assets | 2,255 | 2,839 | 3,569 | 3,676 | 4,312 | 4,811 | 5,281 | 7,374 | 8,074 | 12,888 | 16,117 | 16,941 | 18,513 |
| Total Assets | 5,751 | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,414 | 18,490 | 20,342 | 51,742 | 55,753 | 58,540 | 62,760 |
Below is a detailed analysis of the balance sheet data for Biocon Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 668.00 Cr.. The value appears strong and on an upward trend. It has increased from 600.00 Cr. (Mar 2025) to 668.00 Cr., marking an increase of 68.00 Cr..
- For Reserves, as of Sep 2025, the value is 26,135.00 Cr.. The value appears strong and on an upward trend. It has increased from 21,044.00 Cr. (Mar 2025) to 26,135.00 Cr., marking an increase of 5,091.00 Cr..
- For Borrowings, as of Sep 2025, the value is 16,536.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 18,362.00 Cr. (Mar 2025) to 16,536.00 Cr., marking a decrease of 1,826.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 19,421.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18,534.00 Cr. (Mar 2025) to 19,421.00 Cr., marking an increase of 887.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 62,760.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 58,540.00 Cr. (Mar 2025) to 62,760.00 Cr., marking an increase of 4,220.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 37,262.00 Cr.. The value appears strong and on an upward trend. It has increased from 31,963.00 Cr. (Mar 2025) to 37,262.00 Cr., marking an increase of 5,299.00 Cr..
- For CWIP, as of Sep 2025, the value is 4,651.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8,508.00 Cr. (Mar 2025) to 4,651.00 Cr., marking a decrease of 3,857.00 Cr..
- For Investments, as of Sep 2025, the value is 2,333.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,127.00 Cr. (Mar 2025) to 2,333.00 Cr., marking an increase of 1,206.00 Cr..
- For Other Assets, as of Sep 2025, the value is 18,513.00 Cr.. The value appears strong and on an upward trend. It has increased from 16,941.00 Cr. (Mar 2025) to 18,513.00 Cr., marking an increase of 1,572.00 Cr..
- For Total Assets, as of Sep 2025, the value is 62,760.00 Cr.. The value appears strong and on an upward trend. It has increased from 58,540.00 Cr. (Mar 2025) to 62,760.00 Cr., marking an increase of 4,220.00 Cr..
Notably, the Reserves (26,135.00 Cr.) exceed the Borrowings (16,536.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -177.00 | 695.00 | 388.00 | 978.00 | 827.00 | -1.00 | -1.00 | -3.00 | -4.00 | -16.00 | -13.00 | -15.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 76 | 91 | 78 | 83 | 94 | 86 | 71 | 77 | 92 | 117 | 154 | 131 |
| Inventory Days | 116 | 132 | 153 | 160 | 161 | 199 | 263 | 304 | 309 | 423 | 368 | 346 |
| Days Payable | 107 | 125 | 172 | 187 | 224 | 231 | 243 | 246 | 216 | 383 | 467 | 460 |
| Cash Conversion Cycle | 85 | 98 | 59 | 57 | 31 | 53 | 91 | 134 | 184 | 157 | 55 | 18 |
| Working Capital Days | -31 | -19 | -12 | 24 | 6 | -2 | -31 | 8 | 71 | 3 | -68 | -63 |
| ROCE % | 15% | 12% | 9% | 12% | 8% | 13% | 12% | 10% | 9% | 6% | 6% | 6% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Contra Fund | 16,770,774 | 1.83 | 463.71 | 16,770,774 | 2025-04-22 17:25:40 | 0% |
| Mirae Asset Large Cap Fund | 10,709,389 | 0.79 | 296.11 | 10,709,389 | 2025-04-22 17:25:40 | 0% |
| SBI Balanced Advantage Fund | 10,021,205 | 0.99 | 277.09 | 10,021,205 | 2025-04-22 17:25:40 | 0% |
| Quant Flexi Cap Fund | 5,611,098 | 3.73 | 155.15 | 5,611,098 | 2025-04-22 17:25:40 | 0% |
| Quant Mid Cap Fund | 4,100,000 | 2.09 | 113.37 | 4,100,000 | 2025-04-22 17:25:40 | 0% |
| Kotak Equity Arbitrage Fund - Regular Plan | 4,025,000 | 0.28 | 111.29 | 4,025,000 | 2025-04-22 17:25:40 | 0% |
| SBI Arbitrage Opportunities Fund | 3,397,500 | 0.34 | 93.94 | 3,397,500 | 2025-04-22 17:25:40 | 0% |
| ICICI Prudential India Opportunities Fund | 3,114,146 | 0.5 | 86.11 | 3,114,146 | 2025-04-22 17:25:40 | 0% |
| Sundaram Mid Cap Fund | 3,080,023 | 0.83 | 85.16 | 3,080,023 | 2025-04-22 17:25:40 | 0% |
| Sundaram Mid Cap Fund - Institutional Plan | 3,080,023 | 0.83 | 85.16 | 3,080,023 | 2025-04-22 17:25:40 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 8.46 | 8.55 | 3.88 | 5.44 | 6.24 |
| Diluted EPS (Rs.) | 8.46 | 8.54 | 3.87 | 5.42 | 6.19 |
| Cash EPS (Rs.) | 25.96 | 24.58 | 16.02 | 14.93 | 13.59 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 180.27 | 210.51 | 187.31 | 78.87 | 70.09 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 180.28 | 210.52 | 187.31 | 78.88 | 70.10 |
| Revenue From Operations / Share (Rs.) | 127.12 | 122.90 | 93.07 | 68.17 | 59.22 |
| PBDIT / Share (Rs.) | 36.44 | 34.68 | 24.05 | 18.18 | 15.89 |
| PBIT / Share (Rs.) | 22.38 | 21.62 | 14.78 | 11.40 | 9.93 |
| PBT / Share (Rs.) | 15.71 | 13.40 | 8.86 | 9.91 | 9.56 |
| Net Profit / Share (Rs.) | 11.91 | 11.51 | 6.75 | 8.15 | 7.63 |
| NP After MI And SOA / Share (Rs.) | 8.44 | 8.52 | 3.85 | 5.40 | 6.17 |
| PBDIT Margin (%) | 28.66 | 28.22 | 25.84 | 26.67 | 26.83 |
| PBIT Margin (%) | 17.60 | 17.58 | 15.88 | 16.72 | 16.77 |
| PBT Margin (%) | 12.36 | 10.90 | 9.52 | 14.54 | 16.14 |
| Net Profit Margin (%) | 9.36 | 9.36 | 7.24 | 11.95 | 12.88 |
| NP After MI And SOA Margin (%) | 6.63 | 6.92 | 4.14 | 7.92 | 10.42 |
| Return on Networth / Equity (%) | 4.68 | 5.16 | 2.58 | 7.69 | 9.83 |
| Return on Capital Employeed (%) | 6.04 | 6.37 | 4.07 | 8.26 | 8.32 |
| Return On Assets (%) | 1.72 | 1.82 | 0.88 | 3.17 | 3.99 |
| Long Term Debt / Equity (X) | 0.57 | 0.65 | 0.85 | 0.47 | 0.39 |
| Total Debt / Equity (X) | 0.82 | 0.79 | 0.99 | 0.58 | 0.47 |
| Asset Turnover Ratio (%) | 0.26 | 0.27 | 0.30 | 0.12 | 0.17 |
| Current Ratio (X) | 1.14 | 0.98 | 1.45 | 2.19 | 1.81 |
| Quick Ratio (X) | 0.79 | 0.66 | 0.95 | 1.59 | 1.36 |
| Inventory Turnover Ratio (X) | 3.09 | 1.10 | 0.97 | 0.75 | 0.81 |
| Dividend Payout Ratio (NP) (%) | 5.92 | 17.61 | 12.96 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 2.22 | 6.95 | 3.80 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 94.08 | 82.39 | 87.04 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 97.78 | 93.05 | 96.20 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 4.87 | 4.27 | 6.89 | 32.29 | 33.05 |
| Interest Coverage Ratio (Post Tax) (X) | 2.49 | 2.43 | 3.63 | 17.12 | 16.82 |
| Enterprise Value (Cr.) | 60668.27 | 50669.85 | 44766.88 | 44360.07 | 51477.10 |
| EV / Net Operating Revenue (X) | 3.98 | 3.43 | 4.01 | 5.42 | 7.24 |
| EV / EBITDA (X) | 13.87 | 12.17 | 15.50 | 20.32 | 26.99 |
| MarketCap / Net Operating Revenue (X) | 2.68 | 2.15 | 2.22 | 4.91 | 6.90 |
| Retention Ratios (%) | 94.07 | 82.38 | 87.03 | 0.00 | 0.00 |
| Price / BV (X) | 1.89 | 1.60 | 1.39 | 4.76 | 6.51 |
| Price / Net Operating Revenue (X) | 2.68 | 2.15 | 2.22 | 4.91 | 6.90 |
| EarningsYield | 0.02 | 0.03 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Biocon Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.46. This value is within the healthy range. It has decreased from 8.55 (Mar 24) to 8.46, marking a decrease of 0.09.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.46. This value is within the healthy range. It has decreased from 8.54 (Mar 24) to 8.46, marking a decrease of 0.08.
- For Cash EPS (Rs.), as of Mar 25, the value is 25.96. This value is within the healthy range. It has increased from 24.58 (Mar 24) to 25.96, marking an increase of 1.38.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 180.27. It has decreased from 210.51 (Mar 24) to 180.27, marking a decrease of 30.24.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 180.28. It has decreased from 210.52 (Mar 24) to 180.28, marking a decrease of 30.24.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 127.12. It has increased from 122.90 (Mar 24) to 127.12, marking an increase of 4.22.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 36.44. This value is within the healthy range. It has increased from 34.68 (Mar 24) to 36.44, marking an increase of 1.76.
- For PBIT / Share (Rs.), as of Mar 25, the value is 22.38. This value is within the healthy range. It has increased from 21.62 (Mar 24) to 22.38, marking an increase of 0.76.
- For PBT / Share (Rs.), as of Mar 25, the value is 15.71. This value is within the healthy range. It has increased from 13.40 (Mar 24) to 15.71, marking an increase of 2.31.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 11.91. This value is within the healthy range. It has increased from 11.51 (Mar 24) to 11.91, marking an increase of 0.40.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.44. This value is within the healthy range. It has decreased from 8.52 (Mar 24) to 8.44, marking a decrease of 0.08.
- For PBDIT Margin (%), as of Mar 25, the value is 28.66. This value is within the healthy range. It has increased from 28.22 (Mar 24) to 28.66, marking an increase of 0.44.
- For PBIT Margin (%), as of Mar 25, the value is 17.60. This value is within the healthy range. It has increased from 17.58 (Mar 24) to 17.60, marking an increase of 0.02.
- For PBT Margin (%), as of Mar 25, the value is 12.36. This value is within the healthy range. It has increased from 10.90 (Mar 24) to 12.36, marking an increase of 1.46.
- For Net Profit Margin (%), as of Mar 25, the value is 9.36. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 9.36.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.63. This value is below the healthy minimum of 8. It has decreased from 6.92 (Mar 24) to 6.63, marking a decrease of 0.29.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.68. This value is below the healthy minimum of 15. It has decreased from 5.16 (Mar 24) to 4.68, marking a decrease of 0.48.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.04. This value is below the healthy minimum of 10. It has decreased from 6.37 (Mar 24) to 6.04, marking a decrease of 0.33.
- For Return On Assets (%), as of Mar 25, the value is 1.72. This value is below the healthy minimum of 5. It has decreased from 1.82 (Mar 24) to 1.72, marking a decrease of 0.10.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.57. This value is within the healthy range. It has decreased from 0.65 (Mar 24) to 0.57, marking a decrease of 0.08.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.82. This value is within the healthy range. It has increased from 0.79 (Mar 24) to 0.82, marking an increase of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.26. It has decreased from 0.27 (Mar 24) to 0.26, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 1.5. It has increased from 0.98 (Mar 24) to 1.14, marking an increase of 0.16.
- For Quick Ratio (X), as of Mar 25, the value is 0.79. This value is below the healthy minimum of 1. It has increased from 0.66 (Mar 24) to 0.79, marking an increase of 0.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.09. This value is below the healthy minimum of 4. It has increased from 1.10 (Mar 24) to 3.09, marking an increase of 1.99.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 5.92. This value is below the healthy minimum of 20. It has decreased from 17.61 (Mar 24) to 5.92, marking a decrease of 11.69.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 2.22. This value is below the healthy minimum of 20. It has decreased from 6.95 (Mar 24) to 2.22, marking a decrease of 4.73.
- For Earning Retention Ratio (%), as of Mar 25, the value is 94.08. This value exceeds the healthy maximum of 70. It has increased from 82.39 (Mar 24) to 94.08, marking an increase of 11.69.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 97.78. This value exceeds the healthy maximum of 70. It has increased from 93.05 (Mar 24) to 97.78, marking an increase of 4.73.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 4.87. This value is within the healthy range. It has increased from 4.27 (Mar 24) to 4.87, marking an increase of 0.60.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.49. This value is below the healthy minimum of 3. It has increased from 2.43 (Mar 24) to 2.49, marking an increase of 0.06.
- For Enterprise Value (Cr.), as of Mar 25, the value is 60,668.27. It has increased from 50,669.85 (Mar 24) to 60,668.27, marking an increase of 9,998.42.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.98. This value exceeds the healthy maximum of 3. It has increased from 3.43 (Mar 24) to 3.98, marking an increase of 0.55.
- For EV / EBITDA (X), as of Mar 25, the value is 13.87. This value is within the healthy range. It has increased from 12.17 (Mar 24) to 13.87, marking an increase of 1.70.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.68. This value is within the healthy range. It has increased from 2.15 (Mar 24) to 2.68, marking an increase of 0.53.
- For Retention Ratios (%), as of Mar 25, the value is 94.07. This value exceeds the healthy maximum of 70. It has increased from 82.38 (Mar 24) to 94.07, marking an increase of 11.69.
- For Price / BV (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has increased from 1.60 (Mar 24) to 1.89, marking an increase of 0.29.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.68. This value is within the healthy range. It has increased from 2.15 (Mar 24) to 2.68, marking an increase of 0.53.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Biocon Ltd:
- Net Profit Margin: 9.36%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.04% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.68% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2.49
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.79
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 109 (Industry average Stock P/E: 52.55)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.82
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.36%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 20th K.M. Hosur Road, Bengaluru Karnataka 560100 | investor.relations@biocon.com http://www.biocon.com |
| Management | |
|---|---|
| Name | Position Held |
| Ms. Kiran Mazumdar Shaw | Executive Chairperson |
| Mr. Siddharth Mittal | Managing Director & CEO |
| Prof. Ravi Rasendra Mazumdar | Non Exe.Non Ind.Director |
| Mr. Eric Vivek Mazumdar | Non Exe.Non Ind.Director |
| Mr. Meleveetil Damodaran | Lead Independent Director |
| Dr. Vijay Kumar Kuchroo | Independent Director |
| Mr. Bobby Kanubhai Parikh | Independent Director |
| Mr. Peter John Bains | Independent Director |
| Mr. Naina Lal Kidwai | Independent Director |
Biocon Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹307.50 |
| Previous Day | ₹304.70 |
FAQ
What is the intrinsic value of Biocon Ltd?
Biocon Ltd's intrinsic value (as of 05 December 2025) is 831.22 which is 114.23% higher the current market price of 388.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 51,921 Cr. market cap, FY2025-2026 high/low of 425/291, reserves of ₹26,135 Cr, and liabilities of 62,760 Cr.
What is the Market Cap of Biocon Ltd?
The Market Cap of Biocon Ltd is 51,921 Cr..
What is the current Stock Price of Biocon Ltd as on 05 December 2025?
The current stock price of Biocon Ltd as on 05 December 2025 is 388.
What is the High / Low of Biocon Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Biocon Ltd stocks is 425/291.
What is the Stock P/E of Biocon Ltd?
The Stock P/E of Biocon Ltd is 109.
What is the Book Value of Biocon Ltd?
The Book Value of Biocon Ltd is 200.
What is the Dividend Yield of Biocon Ltd?
The Dividend Yield of Biocon Ltd is 0.13 %.
What is the ROCE of Biocon Ltd?
The ROCE of Biocon Ltd is 6.25 %.
What is the ROE of Biocon Ltd?
The ROE of Biocon Ltd is 4.76 %.
What is the Face Value of Biocon Ltd?
The Face Value of Biocon Ltd is 5.00.